Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.51 |
| ▸ | DRD4 | P21917 | 4/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880873 | 1.00 | DRD2 (0.51) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL30833222 | 1.00 | DRD2 (0.51) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL10817485 | 0.93 | OPRK1 (0.52) | DRD2DRD4DRD3SLC6A2OPRK1 | |
| Trifluoroacetic Acid SCHEMBL30201583 | 0.87 | LTA4H (0.48) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL7491794 | 0.85 | DRD4 (0.41) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL8329958 | 0.85 | DRD4 (0.41) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL7495709 | 0.85 | DRD4 (0.41) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL3881484 | 0.84 | DRD2 (0.48) | DRD2DRD4DRD3LTA4HMAPT | |
| SCHEMBL30833195 | 0.84 | DRD2 (0.48) | DRD2DRD4DRD3LTA4HMAPT | |
| SCHEMBL3881487 | 0.84 | DRD2 (0.48) | DRD2DRD4DRD3LTA4HMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
| EP-1891064-A1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | Laboratorios Almirall, S.A. (ES) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006133802-A1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | CCR1, CCR3, CCR8 | DRD2 2247/4885DRD4 3495/4885DRD3 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.